Stoke Therapeutics
STOK
130 hedge funds and large institutions have $640M invested in Stoke Therapeutics in 2024 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 40 increasing their positions, 41 reducing their positions, and 16 closing their positions.
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
10% more funds holding
Funds holding: 118 → 130 (+12)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.96% less ownership
Funds ownership: 110.57% → 109.61% (-0.96%)
2% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 41
10% less capital invested
Capital invested by funds: $715M → $640M (-$75M)
86% less call options, than puts
Call options by funds: $38K | Put options by funds: $263K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$39M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$24.6M |
| 3 |
RI
RTW Investments
New York
|
+$5.79M |
| 4 |
BlackRock
New York
|
+$3.9M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$3.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ST
Skorpios Trust
Limassol,
Cyprus
|
-$24.6M |
| 2 |
Morgan Stanley
New York
|
-$9.44M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$8.84M |
| 4 |
Jane Street
New York
|
-$3.91M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.13M |
STOK Hedge Fund Activity: Q4 2024 in Review
130 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q4 2024, worth a combined $640M — down 10% from $715M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new STOK positions and 16 closed out — a net gain of 13 holders — while 40 added to existing stakes and 41 trimmed.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $39M. The largest seller was Skorpios Trust, cutting an estimated $24.6M.
- 130 institutional investors held Stoke Therapeutics (STOK) as of Q4 2024, up from 118 in Q3 2024.
- Funds reported $640M of Stoke Therapeutics stock for Q4 2024, down 10% quarter-over-quarter.
- 29 funds opened new Stoke Therapeutics positions in Q4 2024 and 16 closed out, a net change of +13 holders.
- The largest Stoke Therapeutics buyer in Q4 2024 was Toronto Dominion Bank, an estimated $39M added.
- The largest Stoke Therapeutics seller in Q4 2024 was Skorpios Trust, an estimated $24.6M sold.
Based on aggregated 13F filings for Q4 2024.